Active	Status	Sponsor type	Region	Phase	Filter
6 Active 15 Inactive 21 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Armstrong, April W
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis	Recruiting	3	1300	Europe, Canada, Japan, US, RoW	TAK-279	Takeda	Plaque Psoriasis	05/26	05/26
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment	Active, not recruiting	3	693	Europe, Canada, Japan, US, RoW	TAK-279, Placebo, Apremilast	Takeda	Plaque Psoriasis	08/25	04/26
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis	Recruiting	2	60	Canada, US	Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo	Apollo Therapeutics Ltd	Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic	02/25	06/25